Harvard Bioscience Inc(HBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 4 at 4:00 PM ET (Korea 11/5 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.32 | Insider Own | 7.15% | Shs Outstand | 4.5M | Perf Week | 2.26% |
| Market Cap | 0.04B | Forward P/E | 184.49 | EPS next Y | 104.38% | Insider Trans | - | Shs Float | 4.2M | Perf Month | 0.58% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.33 | Inst Own | 41.71% | Short Float | 1.19% | Perf Quarter | 39.1% |
| Income | -0.01B | P/S | 0.45 | EPS this Y | -433.33% | Inst Trans | 3.19% | Short Ratio | 2.59 | Perf Half Y | 18.92% |
| Sales | 0.09B | P/B | 5.28 | EPS next 5Y | - | ROA | -13.32% | Short Interest | 0.05M | Perf YTD | 28.74% |
| Book/sh | 1.63 | P/C | 6.03 | EPS past 3/5Y | -77.14% -44.59% | ROE | -89.95% | 52W High | -5.38% ($9.10) | Perf Year | 39.7% |
| Cash/sh | 1.43 | P/FCF | - | Sales past 3/5Y | -8.6% -3.25% | ROIC | -20.81% | 52W Low | 115.25% ($4.00) | Perf 3Y | -79.98% |
| Dividend Est. | - | EV/EBITDA | 12.88 | EPS Y/Y TTM | 82.17% | Gross Margin | 54.35% | Volatility(W/M) | 4.09% 4.14% | Perf 5Y | -89.21% |
| Dividend TTM | - | EV/Sales | 0.88 | Sales Y/Y TTM | -1.06% | Oper. Margin | 0.65% | ATR (14) | 0.31 | Perf 10Y | -64.13% |
| Dividend Ex-Date | - | Quick Ratio | 0.98 | EPS Q/Q | -24.83% | Profit Margin | -11.86% | RSI (14) | 57.8 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | 11.13% | SMA20 | 2.75% ($8.38) | Beta | 1.47 | Target Price | $10.25 |
| Payout | - | Debt/Eq | 5.96 | Earnings | 2026/11/10 | SMA50 | 5.15% ($8.19) | Rel Volume | 0.53 | Prev Close | $8.67 |
| Employees | 339 | LT Debt/Eq | 5.74 | EPS/Sales Surpr. | 33.33% 5.95% | SMA200 | 32.89% ($6.48) | Avg Volume(3M) | 0.02M | Price | $8.61 |
| IPO | 2000/12/7 | Option/Short | No/Yes | Trades | 277 | Volume | 10,354 | Change | -0.69% |
🔬 This is a US small- to mid-cap life sciences tools company that manufactures and sells precision laboratory instruments and consumables used across a wide range of life science research applications, including electrophysiology, cell analysis, animal telemetry, electroporation, and laboratory fluid handling.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
Next earnings report: November 10
5 days to go.
HBIO keeps an operating profit but posts a net loss
Of every $100 in sales, $0.65 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -433.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $45. Peers typically go for $255.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -89.2%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 41.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DCOR US Core Equity 1 Portfolio ETF Class Shares <0.01% 
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
DFSU Dimensional US Sustainability Core 1 ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% It ranks #42 of 51 in the industry
Based on market cap of $39M.
DXR#40 Daxor Corp $52M PER 7.3 
DAVI#41 Davion Healthcare Plc $42M PER - HBIO#42 Harvard Bioscience Inc $39M PER - 
NEPH#43 Nephros Inc $35M PER 20.8 
MLSS#44 Milestone Scientific Inc $30M PER - 
FAQ
What kind of company is HBIO?
HBIO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of HBIO?
The market cap of HBIO is approximately $39M, ranking 4,959 within its sector.
What is the 52-week high and low for HBIO?
HBIO has recorded a 52-week high of $9.10 and a low of $4.00.
